Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.58 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACP3 | P15309 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762200 | 1.00 | KCNA5 (0.58) | KCNA5SCN5AHSD11B1METAP2METAP1 | |
| SCHEMBL3574304 | 1.00 | KCNA5 (0.58) | KCNA5SCN5AHSD11B1METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL1762465 | 0.99 | KCNA5 (0.57) | KCNA5SCN5AHSD11B1METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL1762349 | 0.99 | KCNA5 (0.57) | KCNA5SCN5AHSD11B1METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL1762316 | 0.77 | SLC18A3 (0.43) | KCNA5SCN5AMETAP2METAP1MEN1 | |
| Hydrochloric Acid SCHEMBL1762428 | 0.77 | SLC18A3 (0.43) | KCNA5SCN5AMETAP2METAP1MEN1 | |
| Hydrochloric Acid SCHEMBL5949221 | 0.77 | SLC18A3 (0.43) | KCNA5SCN5AMETAP2METAP1MEN1 | |
| SCHEMBL2124869 | 0.76 | KCNA5 (0.39) | KCNA5SCN5AHSD11B1METAP2METAP1 | |
| SCHEMBL2122586 | 0.76 | KCNA5 (0.39) | KCNA5SCN5AHSD11B1METAP2METAP1 | |
| SCHEMBL2125605 | 0.76 | KCNA5 (0.39) | KCNA5SCN5AHSD11B1METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188140-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. | 2012-05-29 | — | — | US | disclosed |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-20110118329-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2011-05-19 | — | — | US | disclosed |
| US-7820712-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2010-10-26 | — | — | US | disclosed |
| US-7674820-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2010-03-09 | — | — | US | disclosed |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090041841-A1 | CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS | CARDIOME PHARMA CORP. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20080188547-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2008-08-07 | — | — | US | disclosed |
| US-7345086-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-20060135536-A9 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2006-06-22 | — | — | US | disclosed |
| US-20050070552-A1 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2005-03-31 | — | — | US | disclosed |
| US-20050026993-A1 | Uses of ion channel modulating compounds | CORREVIO CANADA CORP. (CA) | 2005-02-03 | — | — | US | disclosed |
| WO-2004098525-A9 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP (CA) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041841-A1 | CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS | KCNN3, KCNN2, KCNN1 | KCNA5 78/4885SCN5A 59/4885HSD11B1 3022/4885 |
| US-20050070552-A1 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | KCNA5 45/4885SCN5A 71/4885HSD11B1 3797/4885 |
| US-20050026993-A1 | Uses of ion channel modulating compounds | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885HSD11B1 3817/4885 |
| US-20060135536-A9 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | KCNA5 45/4885SCN5A 71/4885HSD11B1 3797/4885 |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNN2 | KCNA5 31/4885SCN5A 59/4885HSD11B1 3790/4885 |
| US-20110118329-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885HSD11B1 3817/4885 |
| US-20080188547-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885HSD11B1 3817/4885 |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNJ2 | KCNA5 34/4885SCN5A 64/4885HSD11B1 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.